3.3 Neuromuscular Blockade - Depolarizing vs Non-Depolarizing Agents

Neuromuscular Blockade — Depolarizing vs Non-Depolarizing Agents

Neuromuscular blocking agents (NMBAs) are essential components of Rapid Sequence Induction. By binding to nicotinic acetylcholine ($ACh$) receptors at the motor endplate of the neuromuscular junction, NMBAs produce complete skeletal muscle paralysis. Transport paramedics must understand the functional differences between depolarizing and non-depolarizing paralytics, as misapplication in high-risk patient populations can precipitate fatal hyperkalemic cardiac arrest or trigger hypermetabolic crises.

---

1. Depolarizing Neuromuscular Blockers

Succinylcholine Chloride (Anectine)

• Mechanism of Action: Succinylcholine consists of two linked acetylcholine molecules. It binds to post-synaptic nicotinic $ACh$ receptors at the neuromuscular junction, causing persistent endplate depolarization. This initially manifests as transient muscle twitching (fasciculations), followed by flaccid paralysis because the voltage-gated sodium channels become inactivated and cannot repolarize.
• RSI Dosing: $1.5 - 2.0\text{ mg/kg IV}$ (use $2.0\text{ mg/kg IV}$ in obese patients or $2.0\text{ mg/kg}$ in pediatrics to ensure rapid glottic relaxation).
• Onset & Duration: Onset $45 - 60\text{ seconds}$; Duration $6 - 10\text{ minutes}$.
• Metabolism: Rapidly hydrolyzed in plasma by plasma pseudocholinesterase (butyrylcholinesterase). Only a small fraction of the injected dose reaches the neuromuscular junction.

Pathophysiology of Extrajunctional Receptors & Hyperkalemia

In normal skeletal muscle, succinylcholine administration causes a transient release of intracellular potassium, elevating serum potassium ($K^+$) by $0.5 - 1.0\text{ mEq/L}$. However, in specific pathological states, skeletal muscle undergoes extrajunctional acetylcholine receptor upregulation (alpha-7 cholinergic subunit proliferation spread across the entire muscle cell membrane). When succinylcholine binds to these extrajunctional receptors, massive, uncoordinated potassium efflux occurs, precipitating severe, refractory hyperkalemia and cardiac arrest within minutes.

Absolute Contraindications for Succinylcholine:

1. Denervation Injuries ($> 24-48\text{ hours}$ post-event): Stroke, spinal cord injury, spinal muscular atrophy, or peripheral nerve transection.
2. Major Thermal Burns ($> 24-48\text{ hours}$ post-injury): Extrajunctional receptor expression persists until full tissue healing/grafting occurs (up to 1–2 years).
3. Severe Crush Injuries or Compartment Syndrome ($> 24-48\text{ hours}$): Massive muscle necrosis and receptor upregulation.
4. Chronic Muscular Dystrophies: Duchenne or Becker muscular dystrophy (high risk of rhabdomyolysis and hyperkalemic cardiac arrest).
5. Pre-existing Severe Hyperkalemia: Known $K^+ > 5.5\text{ mEq/L}$ or characteristic ECG changes (peaked T waves, QRS widening).
6. Personal or Family History of Malignant Hyperthermia.
7. Plasma Pseudocholinesterase Deficiency: Genetic variant causing prolonged paralysis lasting several hours.

---

2. Malignant Hyperthermia (MH)

Malignant Hyperthermia is a rare, life-threatening pharmacogenetic autosomal dominant disorder of skeletal muscle triggered by succinylcholine or volatile halogenated anesthetic gases (e.g., sevoflurane, isoflurane).

Pathophysiology

An inherited mutation in the Ryanodine Receptor Type 1 (RYR1) gene impairs calcium channel regulation in the sarcoplasmic reticulum. Exposure to trigger agents causes an uncontrolled surge of calcium into the myoplasm, producing sustained muscle contraction, extreme hypermetabolism, ATP depletion, and cellular destruction.

Clinical Presentation Sequence

1. Earliest Sign: Unexplained, rapid surge in End-Tidal $CO_2$ ($ETCO_2$) resistant to mechanical hyperventilation.
2. Masseter Muscle Spasm (Trismus): Rigid jaw muscle contraction immediately following succinylcholine administration.
3. Skeletal Muscle Rigidity: Total body "board-like" rigidity.
4. Tachycardia & Hyperdynamic Instability: Marked sinus tachycardia, tachypnea, and unstable blood pressure.
5. Metabolic & Respiratory Acidosis: Severe mixed acidosis with profound base deficit and hyperlactatemia.
6. Hyperthermia (Late Sign): Core body temperature rising as fast as $1-2^\circ\text{C}$ every 5 minutes (can exceed $42^\circ\text{C} / 107^\circ\text{F}$).
7. Rhabdomyolysis & Hyperkalemia: Myoglobinuria (dark brown urine), severe hyperkalemia, DIC, and acute kidney injury.

Emergency Management Protocol for Malignant Hyperthermia

• Stop Triggers: Immediately discontinue succinylcholine/volatile anesthetics.
• Hyperventilate: Administer 100% $O_2$ at maximum flow rates with high minute ventilation to clear $CO_2$.
• Administer Dantrolene Sodium:
  • Dose: $2.5\text{ mg/kg IV}$ rapid push bolus, repeated every 5–10 minutes until symptoms subside (up to maximum cumulative dose of $10\text{ mg/kg}$). Reconstitute each 20 mg vial with 60 mL sterile water.
  • Mechanism: Direct skeletal muscle relaxant that binds to the RYR1 receptor, blocking calcium release from the sarcoplasmic reticulum.
• Active Cooling: Apply ice packs to groin, axillae, and neck; perform cold IV fluid resuscitation until core temp drops $< 38.5^\circ\text{C}$.
• Treat Hyperkalemia & Acidosis: Administer Sodium Bicarbonate ($1\text{ mEq/kg}$), Calcium Chloride ($1\text{ g IV}$), Insulin + Dextrose.

---

3. Non-Depolarizing Neuromuscular Blockers

Non-depolarizing NMBAs act as competitive antagonists at post-synaptic nicotinic $ACh$ receptors. They do not cause endplate depolarization, fasciculations, potassium release, or Malignant Hyperthermia.

Rocuronium Bromide (Zemuron)

• Class: Aminosteroid non-depolarizing NMBA.
• RSI Dose: $1.0 - 1.2\text{ mg/kg IV}$ (Note: Standard non-RSI intubation dose is $0.6\text{ mg/kg}$, but $1.2\text{ mg/kg}$ is required in RSI to achieve glottic paralysis within 60 seconds).
• Onset & Duration: Onset $60\text{ seconds}$; Duration $45 - 70\text{ minutes}$ (can extend beyond 90 minutes in hypothermic or elderly patients).
• Advantages: No hyperkalemia risk, no MH risk, excellent intubating conditions comparable to succinylcholine. Ideal paralytic of choice in neurotrauma, burns, and renal failure.

Vecuronium Bromide (Norcuron)

• Class: Aminosteroid non-depolarizing NMBA.
• RSI Dose: $0.1 - 0.15\text{ mg/kg IV}$ (Must be reconstituted from powder form).
• Onset & Duration: Onset $2.5 - 3.0\text{ minutes}$ (significantly slower than rocuronium); Duration $30 - 45\text{ minutes}$.
• Clinical Application: Suboptimal for primary RSI intubation due to prolonged onset time, but commonly utilized for continuous post-intubation paralysis maintenance.

---

4. Reversal Pharmacology: Sugammadex

Sugammadex (Bridion) represents a breakthrough in non-depolarizing neuromuscular blockade reversal.

• Mechanism of Action: Modified $\gamma$-cyclodextrin molecule with a lipophilic core that selectively encapsulates rocuronium (and vecuronium) molecules in a 1:1 ratio in plasma. This creates a concentration gradient, drawing the drug off the nicotinic receptors back into the vascular space for renal excretion.
• Dosing Guidelines:
  • $2\text{ mg/kg IV}$: Routine reversal for moderate block (reappearance of 2 twitches on Train-of-Four [TOF] monitoring).
  • $4\text{ mg/kg IV}$: Reversal for deep block (1–2 post-tetanic counts [PTC]).
  • $16\text{ mg/kg IV}$: Immediate emergency reversal administered 3 minutes after an RSI dose of Rocuronium ($1.2\text{ mg/kg}$). Reverses paralysis within 2 to 3 minutes during a CICO crisis.
• Traditional Reversal Alternative: Neostigmine ($0.04 - 0.07\text{ mg/kg IV}$) combined with Glycopyrrolate ($0.01\text{ mg/kg IV}$) or Atropine. Neostigmine inhibits acetylcholinesterase, increasing $ACh$ concentration. Crucial limitation: Neostigmine cannot reverse a deep neuromuscular block (TOF must show at least 2 twitches) and takes 10–20 minutes to work.

---

Neuromuscular Blocking Agents Comparison